Shinkokai Medical Corporation

Japan

Shinkokai Medical Corporation

Japan
SEARCH FILTERS
Time filter
Source Type

Shinoda Y.,Asahi Soft Drinks Co. | Kametani N.,Asahi Soft Drinks Co. | Uno T.,Asahi Soft Drinks Co. | Okamoto T.,Asahi Soft Drinks Co. | And 3 more authors.
Japanese Pharmacology and Therapeutics | Year: 2015

Objectives We carried out a randomized double-blind crossover study to investigate the effect of carbonated beverage containing resistant maltodextrin (RMD) on the postprandial serum triglyceride. Methods The subjects were 90 healthy volunteers (fasting serum triglyceride: 120-200 mg/dL) and randomly divided into two groups. They ingested the test beverage containing RMD (5 g) or the beverage without RMD (placebo) together with a fat-rich meal (lipid: 41.0 g). Blood samples were drawn before and 2, 3, 4 and 6 hours after ingestion, and the serum triglyceride was measured. Results In comparison with the placebo beverage, the test beverage significantly lowered the postprandial serum triglyceride at 2, 3, 4 and 6 hours after ingestion of the test beverage (2 and 3 hours: P<0.05, 4 and 6 hours: P<0.01). Postprandial RLP-cholesterol elevation also significantly suppressed at 2, 3, 4 and 6 hours after food ingestion as compared with that of the placebo (2, 3 and 6 hours: P<0.05, 4 hours: P<0.01). Conclusions These results indicated that the carbonated beverage containing RMD has inhibitory effect on the elevation of postprandial serum triglyceride.


Shinoda Y.,Asahi Soft Drinks Co. | Kametani N.,Asahi Soft Drinks Co. | Uno T.,Asahi Soft Drinks Co. | Okamoto T.,Asahi Soft Drinks Co. | And 4 more authors.
Japanese Pharmacology and Therapeutics | Year: 2014

Objectives: We developed carbonated beverage containing resistant maltodextrin (RMD). A randomized, double-blind crossover study was carried out to investigate whether the beverage would suppress the postprandial elevation of the serum triglyceride (TG) levels, remnant like lipoprotein particle (RLP)-cholesterol levels. Also, two randomized double-blind placebo-controlled studies were carried out to assess the safety of excessive or long-term intake of the beverage. Methods: The subjects were 90 healthy volunteers (serum TG : 120-200 mg/dL). The subjects ingested a test beverage containing RMD (5 g) or beverage without RMD (placebo) together with fat-rich meal (lipid : 42.1 g). Blood samples were drawn before and 2, 3, 4 and 6 hours after ingestion, and the serum triglyceride levels were measured. The subject for safety evaluation of long-term intake was 30 healthy volunteers, including 10 volunteers whose serum TG levels were 150-200 mg/dL. They consumed one bottle of test beverage (485 mL/bottle) containing RMD (5 g) at a meal per day for 12 weeks. The subject for safety evaluation of excessive intake was 30 healthy volunteers, including 10 volunteers whose serum TG levels were 150-200 mg/dL. They consumed one bottle of test beverage containing RMD (15 g) at a meal per day for 4 weeks. Results: Intake of RMD beverage significantly suppressed the level of serum TG observed at 2, 3 and 4 hours after food ingestion as compared with that of the placebo (P< 0.05). Postprandial RLP-cholesterol elevation also significantly suppressed at 3, 4 and 6 hours after food ingestion as compared with that of the placebo (P<0.05). Also, there were no clinical problems in the blood examinations and physical examinations. No adverse reactions were observed. Conclusions: These results indicated that intake of the RMD supplemented beverage suppresses postprandial serum triglyceride levels without any safety problem.


Tanaka T.,Suntory Wellness Ltd | Nakamura J.,Suntory Wellness Ltd | Kitagawa Y.,Suntory Wellness Ltd | Shibata H.,Suntory Wellness Ltd | Sugimura H.,Shinkokai Medical Corporation
Japanese Pharmacology and Therapeutics | Year: 2011

Objectives: A randomized double-blind placebo-controlled crossover study was conducted on 90 subjects with high-normal fasting serum triglyceride levels and mild hypertriglyceridemia in order to evaluate the effect of carbonated beverages containing resistant maltodextrin on postprandial serum triglyceride elevation. Methods: The subjects were 90 healthy volunteers (fasting serum triglyceride : 120-200 mg/dL). The subjects were randomly divided into two groups and ingested a high fat meal (42.2 g fat) and either a test beverage containing 5 g (as dietary fiber) of resistant maltodextrin or a placebo beverage without resistant maltodextrin. Serum triglyceride elevation was determined before and 2, 3, 4, and 6 hours after ingestion of the high fat meal. Results: Compared to the placebo beverage, the test beverage significantly lowered the value of postprandial serum triglyceride at 3 and 4 hours after the high fat meal was ingested (p<0.05). In addition, within a subgroup of subjects with fasting serum triglyceride levels 150-200 mg/dL, the value of postprandial serum triglyceride was significantly lowered by the test beverage 4 hours after the high fat meal was ingested when compared with the placebo beverage (p<0.05). Conclusions: These results demonstrated that the carbonated beverage containing resistant maltodextrin taken with a meal has an inhibitory effect on the postprandial serum triglyceride elevation in subjects with high-normal fasting serum triglyceride levels and mild hypertriglyceridemia.


Katabami T.,St. Marianna University School of Medicine | Kato H.,St. Marianna University School of Medicine | Asahina T.,Life Planning Center | Hinohara S.,Life Planning Center | And 5 more authors.
Endocrine Journal | Year: 2010

To examine the association between late-onset hypogonadism (LOH) and metabolic syndrome (Mets) or insulin resistance in the Japanese adult male population, we evaluated anthropometric parameters, indices of glucose and lipid metabolism, and hormones related to sexual function in 274 men (mean age: 46.0 ± 11 years) who underwent general health checks. Seventy subjects (25.5%) were diagnosed as having Mets, while the frequency of LOH was 8.0%. Glycated hemoglobin was normal in the majority of participants (94.9%). The serum free testosterone (FT) level was significantly lower in the Mets (+) group than in the Mets (-) group (11.7 ± 4.0 vs. 14.7 ± 4.6 pg/mL, p<0.0001). FT decreased significantly along with an increase in the number of Mets components. Likewise, the number of Mets components showed a significant difference among the eugonadal, borderline, and hypogonadal groups (2.2 ± 1.4, 1.5 ± 1.4, and 0.9 ± 1.1, respectively). After adjustment for age, body mass index (BMI), and waist circumference (WC), FT was still significantly correlated with Mets (standard partial regression coefficient = - 0.0971; 95% confidence interval = - 0.1936 ~ - 0.0006; p = 0.048). A compensatory increase of gonadotropins was not seen in the hypogonadal group. Among Japanese men who were mainly without diabetes, FT was associated with Mets independently of age, BMI, and WC. Mets and insulin resistance may decrease serum testosterone via induction of hypogonadotrophic hypogonadism, and the reduction of testosterone may in turn cause further obesity and insulin resistance, consequently initiating a vicious cycle.


Patent
Kyoto University, Wakayama Medical University, Ito, Shinkokai Medical Corporation and Toyo Kohan Co. | Date: 2016-07-20

The present invention provides a test method and an evaluation kit for determining the risk of antithyroid drug-induced agranulocytosis. More particularly, it provides a test method for determining the risk of antithyroid drug-induced agranulocytosis, including testing susceptibility polymorphism to antithyroid drug-induced agranulocytosis, and determining the risk of antithyroid drug-induced agranulocytosis, and an evaluation kit for the risk of antithyroid drug-induced agranulocytosis, containing a polynucleotide capable of detecting susceptibility polymorphism to antithyroid drug-induced agranulocytosis.


Patent
Kyoto University, Wakayama Medical University, Shinkokai Medical Corporation and Toyo Kohan Co. | Date: 2014-09-11

The present invention provides a test method and an evaluation kit for determining the risk of antithyroid drug-induced agranulocytosis. More particularly, it provides a test method for determining the risk of antithyroid drug-induced agranulocytosis, including testing susceptibility polymorphism to antithyroid drug-induced agranulocytosis, and determining the risk of antithyroid drug-induced agranulocytosis, and an evaluation kit for the risk of antithyroid drug-induced agranulocytosis, containing a polynucleotide capable of detecting susceptibility polymorphism to antithyroid drug-induced agranulocytosis.


Takano A.,Toyo Shinyaku Co. | Kamiya T.,Toyo Shinyaku Co. | Yamaguchi K.,Toyo Shinyaku Co. | Takagaki K.,Toyo Shinyaku Co. | Sugimura H.,Shinkokai Medical Corporation
Japanese Pharmacology and Therapeutics | Year: 2015

Objectives: A randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the effects of powdered black tea containing polydextrose on postprandial serum triglyceride. Methods: The subjects were 90 healthy volunteers whose fasting serum triglyceride levels were from 120 to 199 mg/dL. The subjects were randomly divided into two groups and ingested a fat-rich diet and either a test drink containing 5 g (as dietary fiber) of polydextrose or a placebo drink without polydextrose. Serum triglyceride levels were measured before and at 2, 3,4, and 6 hours after ingestion. Results: The test drink significantly decreased postprandial serum triglyceride levels at 4 hours and area under the curve after the fat-rich diet was ingested, compared to placebo drink (P<0.05). During this study period, no abnormal changes attributed to test drink were observed. Conclusions: These results indicate that powdered black tea containing polydextrose taken with a diet has an inhibitory effect on the postprandial serum triglyceride elevation.


Yasutake Y.,Suntory Business Expert Ltd | Hori H.,Suntory Business Expert Ltd | Kitagawa Y.,Suntory Business Expert Ltd | Sugimura H.,Shinkokai Medical Corporation
Japanese Pharmacology and Therapeutics | Year: 2015

Objectives To evaluate the safety of excessive intake of tea containing quercetin glucosides in healthy adults including obese subjects. Study design A randomized, double-blind, placebo-controlled, parallel-group study. Methods Forty-eight healthy adults aged 20-64 years old with body mass index (BMI) ≥ 18.5 and<30.0kg/m2 were randomly assigned into two groups and ingested daily one bottle of the tea containing 0 mg or 330 mg of quercetin glucosides for 4 weeks. Results There were no clinically concerning changes or adverse effects related to the test beverage containing quercetin glucosides in this study. Conclusions These results indicated that the tea containing quercetin glucosides was safe for excessive intake.


Kishimoto Y.,Matsutani Chemical Industry Co. | Tachibe M.,Matsutani Chemical Industry Co. | Kitagawa M.,Matsutani Chemical Industry Co. | Nishibata T.,Matsutani Chemical Industry Co. | And 2 more authors.
Japanese Pharmacology and Therapeutics | Year: 2014

Methods: Fifty four healthy female subjects with constipation tendency were recruited for a randomized and placebo-controlled study. After 2-week observation period (Pre-Period), all subjects received 28 g of placebo biscuits (without HXLS) for 2 weeks (Period I). Following Period I, subjects received placebo, low-dose (3.5 g of dietary fiber from HXLS), or highdose (7 g of dietary fiber from HXLS) biscuits for 2 weeks (Period II). During 6-week test period, subjects were requested to record symptoms such as stool frequency, stool volume.Results: Compared to Pre-Period, no significant effect was observed in low-dose group, whereas high-dose group showed significantly higher frequency of defecation during Period II.Conclusion: The investigation revealed that defecation frequency depends on dietary fiber intake and effective amount of dietary fiber from HXLS is 7 g.Objectives: We investigated the efficacy and dose-dependent effect of highly cross-linked starch (HXLS) from tapioca on defecation.


Takii H.,Glico Dairy Products Co. | Nishijima T.,Glico Dairy Products Co. | Takami K.,Glico Dairy Products Co. | Tanaka Y.,Glico Dairy Products Co. | And 4 more authors.
Japanese Pharmacology and Therapeutics | Year: 2012

The aim of this study was to evaluate the changes in intestinal bifidobacteria and the effect on fecal properties in healthy subjects with mild constipation after administration of a fermented milk containing Bifidobacterium animalis subsp. lactis (B. lactis) GCL2505. Volunteers (n=62 ; 15 male, 47 female ; 42.5±10.2 years [mean±SD]) were randomly divided into two groups and given 100 g of fermented milk containing B. lactis GCL2505 (>1×10 7cfu/g) or a placebo daily for 2 weeks in a double-blind crossover study. An increase in the number of total bifidobacteria (sum of B. bifidum, B. breve, B. longum subsp. longum, B. adolescente, B. angulatum, B. catenulatum, B. pseudocatenulatum, B. dentium, B. longum subsp. infantis, and B. lactis) was detected in feces after administration of the B. lactis GCL2505 fermented milk by species- and subspecies-specific real-time polymerase chain reaction analysis. The number of endogenous bifidobacteria species, excluding B. lactis, remained unchanged, and B. lactis became the predominant bifidobacterial species. Defecation frequency and stool quantity increased significantly (p < 0.05) during the B. lactis GCL2505 fermented milk ingesting period compared with placebo. These results indicate that GCL2505-fermented milk contributes to an increase in intestinal bifidobacteria by proliferating itself and to improvements in mild constipation without affecting endogenous bifidobacteria.

Loading Shinkokai Medical Corporation collaborators
Loading Shinkokai Medical Corporation collaborators